<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05071716</url>
  </required_header>
  <id_info>
    <org_study_id>RNLC3131</org_study_id>
    <nct_id>NCT05071716</nct_id>
  </id_info>
  <brief_title>Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis</brief_title>
  <acronym>RED-C-3131</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch Health Americas, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study RNLC3131 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study&#xD;
      to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode&#xD;
      of overt hepatic encephalopathy (OHE) decompensation in advanced liver cirrhosis, defined by&#xD;
      the presence of medically controlled ascites.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first event of overt hepatic encephalopathy requiring hospitalization</measure>
    <time_frame>72 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to all-cause hospitalization</measure>
    <time_frame>72 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">466</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <arm_group>
    <arm_group_label>Rifaximin SSD-40mg IR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin SSD</intervention_name>
    <description>Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily</description>
    <arm_group_label>Rifaximin SSD-40mg IR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Twice Daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participant has a diagnosis of advanced liver cirrhosis with medically controlled&#xD;
             ascites (&gt;30 days) not requiring therapeutic paracentesis (prophylactic variceal&#xD;
             banding allowed if no history of previous variceal bleeding).&#xD;
&#xD;
          2. Participant has a Child-Pugh B Classification (score of 7 to 9 inclusive) without OHE&#xD;
             and a Model End-Stage Liver Disease Sodium (MELD-Na) score of &lt;15 at Visit 1.&#xD;
&#xD;
          3. Participant has a Conn (West Haven Criteria) score of &lt;2 without known neurologic,&#xD;
             psychiatric or iatrogenically induced increase.&#xD;
&#xD;
          4. Participant has a Mini-Mental State Examination (MMSE) score ≥ 24 and demonstrates no&#xD;
             cognitive impairment upon exam at screening and baseline.&#xD;
&#xD;
          5. Participant is at least 18 and ≤70 years of age.&#xD;
&#xD;
          6. Females of childbearing (reproductive) potential must have a negative serum or urine&#xD;
             pregnancy test at screening. All participants must agree to use 2 acceptable methods&#xD;
             of contraception throughout their participation in the study.&#xD;
&#xD;
          7. Participant must be able to independently read, fully understand and provide written&#xD;
             informed consent on the Institutional Review Board (IRB)/Ethics Committee (EC)&#xD;
             approved informed consent form (ICF) without additional support and provide&#xD;
             authorization as appropriate per local privacy regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participant has an active coronavirus disease 2019 (COVID 19) infection that is&#xD;
             unresolved or, in the opinion of the investigator, may affect evaluation of the study&#xD;
             drug or place the subject at undue risk&#xD;
&#xD;
          2. Participant has a history of anaphylaxis or hypersensitivity to rifaximin, rifampin,&#xD;
             rifamycin antimicrobial agents, or any of the components of rifaximin.&#xD;
&#xD;
          3. Participant has a history of drug-induced liver injury, drug rash with eosinophilia&#xD;
             and systemic symptom (DRESS) syndrome.&#xD;
&#xD;
          4. Participant has a history or current clinical suspicion of hepatopulmonary syndrome.&#xD;
&#xD;
          5. Participant has a history of SBP, primary or secondary SBP prophylaxis, EVB, or&#xD;
             AKI-HRS.&#xD;
&#xD;
          6. Participant has a documented history of an OHE episode (Conn score ≥ 2) or has a&#xD;
             history of rifaximin 550 mg and lactulose use for suspected OHE episode.&#xD;
&#xD;
          7. Participant has either: a) no history of ascites -or- b) uncontrolled ascites.&#xD;
&#xD;
          8. Participant has other non-controllable neurological or psychiatric conditions which&#xD;
             may confound the assessment of cognitive function (e.g., dementia, schizophrenia,&#xD;
             etc.).&#xD;
&#xD;
          9. Participants with focal neurological deficits due to a neurological event such as&#xD;
             cerebrovascular accident.&#xD;
&#xD;
         10. Participants with Wernicke's or Wernicke-Korsakoff encephalopathy.&#xD;
&#xD;
         11. Participant has signs of alcohol use disorder, defined as Alcohol Use Disorders&#xD;
             Identification Test (AUDIT-10) score of &gt;7, within 6 months of signing the ICF.&#xD;
&#xD;
         12. Participant has pseudomembranous colitis, abdominal abscess, or clinically significant&#xD;
             strictures and fistulas of the gastrointestinal tract.&#xD;
&#xD;
         13. Participant has epilepsy and experienced a seizure within 12 weeks prior to screening.&#xD;
&#xD;
         14. Participant consumes more than moderate amounts of alcohol, defined as 1 standard&#xD;
             drink per day for women and 2 standard drinks per day for men.&#xD;
&#xD;
         15. Participant has a history of substance abuse &lt; 6 months prior to signing the ICF and&#xD;
             cannot refrain from substance abuse during the study period.&#xD;
&#xD;
         16. Participant is currently taking narcotics, benzodiazepines, or psychoactive medicines&#xD;
             which cannot be discontinued.&#xD;
&#xD;
         17. Participant is currently taking an anticoagulant&#xD;
&#xD;
         18. Participant has been diagnosed with an uncontrolled infection &lt; 4 weeks prior to&#xD;
             screening.&#xD;
&#xD;
         19. Participant has been diagnosed with an upper gastrointestinal bleed from non-variceal&#xD;
             sources &lt; 6 weeks prior to screening.&#xD;
&#xD;
         20. Participant shows the presence of intestinal obstruction or has inflammatory bowel&#xD;
             disease.&#xD;
&#xD;
         21. Participant has undergone bariatric surgery or intestinal resection.&#xD;
&#xD;
         22. Participant has a history of portal vein thrombosis, a history of a transjugular&#xD;
             intrahepatic portosystemic shunt (TIPS) procedure, or plans to undergo a TIPS&#xD;
             procedure.&#xD;
&#xD;
         23. Participant has a history of shunt surgery or direct intrahepatic portocaval shunt&#xD;
             (DIPS) procedure for portal hypertension or plans to undergo a DIPS procedure.&#xD;
&#xD;
         24. Participant has a history of peritoneal dialysis.&#xD;
&#xD;
         25. Participant has undergone prophylactic variceal banding within 2 weeks of screening or&#xD;
             is scheduled to undergo prophylactic variceal banding during the study (Note:&#xD;
             participants with previous prophylactic variceal banding will be allowed to&#xD;
             participate in the study).&#xD;
&#xD;
         26. Participant has Type 1 or Type 2 diabetes that is not adequately controlled in the&#xD;
             opinion of the investigator.&#xD;
&#xD;
         27. Participant has severe co-morbid disease with a life expectancy &lt; 1 year.&#xD;
&#xD;
         28. Participant has active malignancy (except basal carcinoma of the skin), including&#xD;
             active hepatocellular carcinoma (HCC) and/or a past history of HCC. Participants with&#xD;
             resections or ablations of squamous cell carcinoma of the skin, or in situ carcinoma&#xD;
             of the cervix, that occurred greater than 6 months prior to screening and are&#xD;
             considered disease free are eligible for enrollment.&#xD;
&#xD;
         29. Evidence of HCC or a lesion suspicious for HCC within 6 months on ultrasound or&#xD;
             contrast multiphase magnetic resonance imaging (MRI) or computed tomography (CT). If&#xD;
             this imaging is not available, or if alpha-fetoprotein (AFP) ≥ 20 ng/ml at screening,&#xD;
             participants should undergo standard of care diagnostic procedures with their personal&#xD;
             physician to rule out HCC during the screening period.&#xD;
&#xD;
         30. Participant requires hemodialysis.&#xD;
&#xD;
         31. Participant has any condition or circumstance that adversely affects the participant,&#xD;
             could cause noncompliance with treatment or visits, may impact the interpretation of&#xD;
             clinical data, could cause bias, or may otherwise contraindicate the participant's&#xD;
             participation in the study.&#xD;
&#xD;
         32. Participant used any investigational product or device within 30 days or 5 half-lives&#xD;
             of the investigational product (whichever comes first) of providing consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Lahey</last_name>
    <role>Study Director</role>
    <affiliation>Bausch Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Lahey</last_name>
    <phone>908-541-8631</phone>
    <email>john.lahey@bauschhealth.com</email>
  </overall_contact>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>September 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

